Second Sight Medical Products Inc. (EYES) Stock Price Down 3.3%
Second Sight Medical Products Inc. (NASDAQ:EYES)’s share price fell 3.3% during trading on Wednesday . The stock traded as low as $3.55 and last traded at $3.56, with a volume of 93,318 shares changing hands. The stock had previously closed at $3.68.
Several research firms recently commented on EYES. Zacks Investment Research lowered shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Second Sight Medical Products in a report on Tuesday, July 26th.
The stock’s market capitalization is $145.59 million. The firm’s 50 day moving average is $3.95 and its 200 day moving average is $4.40.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.02. During the same quarter last year, the business earned ($0.12) EPS. The business had revenue of $1.04 million for the quarter, compared to analyst estimates of $2.66 million. The firm’s revenue was down 63.0% on a year-over-year basis. Equities analysts expect that Second Sight Medical Products Inc. will post ($0.62) earnings per share for the current fiscal year.
In other Second Sight Medical Products news, Chairman Robert J. Greenberg sold 8,571 shares of the business’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total transaction of $35,141.10. Following the transaction, the chairman now owns 172,911 shares in the company, valued at $708,935.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.